Crinetics Pharmaceuticals, Inc. announced on May 15, 2025, it would present two abstracts at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025. One presentation featured a post-hoc analysis showing investigational paltusotine provided rapid and durable IGF-1 control in surgically naïve acromegaly patients.
This analysis, drawing from three clinical trials (PATHFNDR-1, PATHFNDR-2, and ACROBAT Advance), indicated that paltusotine was well tolerated and achieved IGF-1 normalization in a significant number of patients. These results suggest paltusotine's potential as a viable first-line medical therapy.
Additional research highlighted high discontinuation rates (54%) with existing injectable acromegaly therapies, underscoring the unmet need for oral alternatives. New data from a Phase 1b/2a study of atumelnant in ACTH-dependent Cushing’s syndrome also provided insights into hydrocortisone administration, simplifying disease management for patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.